Healthcare Wrap: Biotron and Cyclopharm Surge as FDA and Guideline Wins Drive Buyers

• Biotron (ASX:BIT) jumped 🟢 33.33% after funding and deal progress around its hepatitis B and Sedarex assets
• Cyclopharm (ASX:CYC) rose 🟢 32.95% as Technegas gained support in a key US lung imaging guideline and the company pushed into COPD research
• 4DMedical (ASX:4DX) slid 🔴 -21.73% even as US hospital adoption continued, showing investors still want clearer revenue visibility
• Across the sector, FDA clearances and Medicare billing changes kept rewarding companies closest to real sales